Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter randomized phase III study to compare capecitabine alone or in combination with trastuzumab in patients with HER2 positive metastatic breast cancer and progression after previous treatment with trastuzumab.

Next Previous
X
Search
Trial Profile

A multicenter randomized phase III study to compare capecitabine alone or in combination with trastuzumab in patients with HER2 positive metastatic breast cancer and progression after previous treatment with trastuzumab.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab (Primary) ; Capecitabine
  • Indications Advanced breast cancer; HER2 negative breast cancer; HER2 positive breast cancer
  • Focus Therapeutic Use
  • Acronyms TBP

    • Most Recent Events

    • 22 Feb 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
    • 05 May 2010 Results of a cost-utility analysis based on this trial have been published in the Annals of Oncology.
    • 07 Apr 2009 New source identified and integrated (United Kingdom Clinical Research Network 1087413)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top